Figure 5.

Functional analysis of the role of Gas6/TAM (Tyro3, Axl, and Mertk) receptor activation in normal and IPF fibroblast invasion. Normal and IPF fibroblasts were treated with the small-molecule inhibitors R428 (2 and 10 μM) and LDC (5 and 25 μM); BIBF1120 (300 nM) or vehicle; and the antibodies S6 (4 μg/ml), anti-Axl (20 μg/ml), or IgG (20 μg/ml). Invasive properties were assessed by (A–D) scratch wound invasion and (E–H) chemotactic invasion for a minimum of 60 hours. Data are shown as a representative of normal (n = 3) and IPF fibroblast (n = 3) lines that were tested under similar conditions. Data are mean ± SEM. CC008-16, CC009-16, IPF02-16, IPF06-15, IPF09-14, and NLw2 are individual cell lines used in our experiments. αAxl = anti-Axl; Axl = anexelekto; BIBF = BIBF1120 (nintedanib); Gas6 = growth arrest–specific 6; IPF = idiopathic pulmonary fibrosis; LDC = LDC1267; Mertk = MER proto-oncogene, tyrosine kinase; Tyro3 = TYRO3 protein tyrosine kinase 3.